Penumbra, Inc. (BMV:PEN)

Mexico flag Mexico · Delayed Price · Currency is MXN
4,775.70
-136.12 (-2.77%)
At close: Aug 18, 2025
Market Cap224.08B +5.2%
Revenue (ttm)25.27B +17.5%
Net Income3.20B +1,168.1%
EPS81.37 +1,155.6%
Shares Outn/a
PE Ratio70.05
Forward PE64.60
Dividendn/a
Ex-Dividend Daten/a
Volume300
Average Volume446
Open4,775.70
Previous Close4,911.82
Day's Range4,775.70 - 4,775.70
52-Week Range3,904.75 - 4,911.82
Betan/a
RSI55.88
Earnings DateApr 30, 2026

About Penumbra

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron ... [Read more]

Industry Surgical and Medical Instruments and Apparatus
Founded 2004
Employees 4,700
Stock Exchange Mexican Stock Exchange
Ticker Symbol PEN

Financial Performance

In 2025, Penumbra's revenue was $1.40 billion, an increase of 17.50% compared to the previous year's $1.19 billion. Earnings were $177.69 million, an increase of 1168.11%.

Financial numbers in USD Financial Statements

News

8 Stocks to Buy as Merger-Mania Takes Over

Wall Street loves growth stories. Venture capitalists love disruption stories.

4 weeks ago - Benzinga

Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

ALAMEDA, Calif., Feb. 25, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended Decembe...

6 weeks ago - PRNewsWire

Boston Scientific announces results for fourth quarter and full year 2025

MARLBOROUGH, Mass., Feb. 4, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.286 billion during the fourth quarter of 2025, growing 15.9 percent on a reported b...

2 months ago - PRNewsWire

Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm as there may be limited time to enforce your rights Shareholders should contact the firm as there may be limited time to enforce your rights

2 months ago - GlobeNewsWire

Boston Scientific to buy Penumbra in $14.5B deal to expand cardiovascular reach

Boston Scientific on Thursday announced plans to acquire Penumbra, a US-based thrombectomy specialist, in a cash-and-stock deal valued at about $14.5 billion, marking one of the largest transactions i...

3 months ago - Invezz

Penumbra Stock Jumps. It's Being Bought by Boston Scientific for $14.5 Billion.

The cash-and-stock acquisition values Penumbra at $374 a share.

3 months ago - Barrons

Boston Scientific is buying Penumbra for $14.5 billion, gaining entry to ‘fast-growing' vascular segments

Penumbra's stock was up about 14% after the deal was announced Thursday morning.

3 months ago - Market Watch

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock

Boston Scientific has agreed to buy thrombectomy company Penumbra for about $15 billion in cash and stock in a deal that bolsters its cardiovascular portfolio.

3 months ago - WSJ

Boston Scientific to buy Penumbra in deal valued at $14.5 billion

Boston Scientific said on Thursday it will buy Penumbra in a deal valued at about $14.5 billion.

3 months ago - Reuters

Penumbra, Inc. Provides Preliminary Update on Fourth Quarter and Full Year 2025 Financial Results

ALAMEDA, Calif., Jan. 15, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today announced certain unaudited and preliminary financial results for the fourth ...

3 months ago - PRNewsWire

Boston Scientific announces agreement to acquire Penumbra, Inc.

Acquisition to expand Boston Scientific's cardiovascular portfolio and further address increasing prevalence of vascular diseases Provides scaled entry into mechanical thrombectomy and neurovascular, ...

3 months ago - PRNewsWire

Penumbra, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference

ALAMEDA, Calif., Dec. 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 44th Annual J.P.

3 months ago - PRNewsWire

Penumbra, Inc. to Present at the Piper Sandler 37th Annual Healthcare Conference

ALAMEDA, Calif. , Nov. 19, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 37th Annual Healthcare Conference on We...

5 months ago - PRNewsWire

Penumbra, Inc. Reports Third Quarter 2025 Financial Results

ALAMEDA, Calif. , Nov. 5, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2025.

5 months ago - PRNewsWire

Latest Data from Landmark STORM-PE Randomized Controlled Trial Demonstrate that CAVT with Anticoagulation Significantly Improves Functional Outcomes for Patients with Pulmonary Embolism

The STORM-PE RCT data presented at the VIVA 2025 Conference showed PE patients treated with CAVT in combination with anticoagulation demonstrated significantly greater improvements in thrombus burden ...

5 months ago - PRNewsWire

Landmark STORM-PE Randomized Controlled Trial Finds Computer Assisted Vacuum Thrombectomy (CAVT) with Anticoagulation Superior to Traditional Anticoagulation Treatment for Pulmonary Embolism

ALAMEDA, Calif. , Oct. 27, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) announced the results of the landmark STORM-PE randomized controlled trial (RCT), which found that the use of mechanical thro...

5 months ago - PRNewsWire

Penumbra, Inc. Schedules Investor Event at TCT Conference on October 26, 2025; Earnings Release and Conference Call for Third Quarter 2025 Scheduled for November 5, 2025

ALAMEDA, Calif. , Oct. 8, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host an investor event on Sunday, October 26, 2025 from 4:00-5:00 PM Pacific Time / 7:00-8:00 PM ...

6 months ago - PRNewsWire

New Survey Shows Management of Blood Clots is Inconsistent, Even for Patients with the Same Risk Profile

Survey Conducted by the Get Out the Clot Campaign, an Initiative Focused on Identifying and Closing Gaps in Patient Care for Blood Clots ALAMEDA, Calif. , Sept. 9, 2025 /PRNewswire/ -- The American Ve...

7 months ago - PRNewsWire

Penumbra, Inc. Names Shruthi Narayan as Company President

ALAMEDA, Calif. , Aug. 27, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today announced the promotion of Shruthi Narayan to President of the company, effe...

8 months ago - PRNewsWire

Penumbra, Inc. to Present at Upcoming Investor Conferences

ALAMEDA, Calif. , Aug. 20, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and times...

8 months ago - PRNewsWire

Penumbra, Inc. to Present at the Canaccord Genuity 45th Annual Growth Conference

ALAMEDA, Calif. , July 30, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity 45th Annual Growth Conference on Tu...

9 months ago - PRNewsWire

Penumbra, Inc. Reports Second Quarter 2025 Financial Results

ALAMEDA, Calif. , July 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2025.

9 months ago - PRNewsWire

Five years after COVID, pharma shares languish in US policy limbo

Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies...

9 months ago - Reuters

Penumbra, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for July 29, 2025

ALAMEDA, Calif. , July 1, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2025 after market clos...

10 months ago - PRNewsWire

Penumbra, Inc. Announces Completion of Enrollment for Landmark STORM-PE Randomized Controlled Trial

STORM-PE is a first-of-its-kind clinical trial comparing computer assisted vacuum thrombectomy (CAVT™) using Penumbra's Lightning Flash™ with anticoagulation versus anticoagulation alone in the treatm...

10 months ago - PRNewsWire